Skip to content
Search

Latest Stories

RPS urges government to ban ‘diet drug’ DNP for human consumption

The Royal Pharmaceutical Society (RPS) is calling on the Home Office to ban the industrial chemical 2,4-Dinitrophenol (DNP), stating it to be unfit for human consumption.

According to National Poison Information Service report 2020/21, DNP has led to 32 deaths since 2007 among those taking it after being supplied online as a ‘diet drug’.


The main use of DNP is in the manufacture of explosives and pesticides. It can also reduce body fat by speeding up the metabolism and is sold by unscrupulous dealers to vulnerable individuals wanting to lose weight. It is highly dangerous to health and should never be used for weight loss.

Responding to the Home Office consultation on changes to the Poisons Act 1972, RPS urged the government to immediately ban DNP to reduce the danger to the public, to prosecute those seeking to profit from DNP and to encourage other countries to do the same.

Between 2007 and 2020, the UK National Poisons Information Service recorded 138 cases of poisoning due to DNP. Of those who presented at hospital between 2007 and 2019 with a history of having taken DNP, 18 per cent died.

RPS President Professor Claire Anderson said: “We welcome the fact that DNP could be added to the Poisons List, which we have been calling for since 2019. But we believe that DNP should be completely banned and not supplied under any circumstances. There is no legitimate human or animal use for DNP and over the last 15 years 32 people have died from taking it.

“We are concerned that DNP is still in circulation and often targeted to image conscious young people who may want to try quick fixes to improve their body image. Don’t ever believe what you see online about DNP – if you want to lose weight, talk to a health professional instead. You’re dicing with death if you buy DNP online.

“If the Home Office will not consider a ban, then as well as adding DNP to the Poisons List to control its supply, legislation should be passed that prohibits the compounding of DNP. This would make it illegal to put DNP into sachets or capsules for human, animal or agricultural use.”

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less